Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ervebo in Healthy Children in Gabon
NCT05130398Phase 2Completed
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoints: Concentration of viral vector in blood, saliva and urine at Day 28, Prevalence and relative risk of solicited adverse events and 1 more. Started Apr 2021; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT05130398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130398.